The European Commission on Wednesday (1 July) refused to speak out against the US decision to buy up most of the world's stock of remdesivir.
The drug, manufactured by the US-based biopharmaceutical company Gilead, has been proven to work against Covid-19.
Two of the most senior European Commission officials, vice-presidents Margaritis Schinas and Valdis Dombrovskis, declined to respond to questions on the US move during a press conference on Wednesday.
Instead, the European...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? LoginNikolaj joined EUobserver in 2012 and covers home affairs. He is originally from Denmark, but spent much of his life in France and in Belgium. He was awarded the King Baudouin Foundation grant for investigative journalism in 2010.
Nikolaj joined EUobserver in 2012 and covers home affairs. He is originally from Denmark, but spent much of his life in France and in Belgium. He was awarded the King Baudouin Foundation grant for investigative journalism in 2010.